Previous 10 | Next 10 |
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that Selwyn M. Vickers, M.D., F.A.C.S., has been elected to serve on the company’s board of directors. This press...
Forma Therapeutics ([[FMTX]] -7.8%) closed an underwritten public offering of ~6.1M common stock, including the exercise in full of underwriters' over-allotment of an additional 795K shares, at a public offering price of $45.25 per share.Gross proceeds of ~$275.8M and ...
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the closing of an underwritten public offering of 6,095,000 shares of its common stock, including the exercise in full by the un...
Four IPOs and one SPAC are scheduled to raise $1.7 billion in the week ahead. Street research is expected for six companies. Lock-up periods will be expiring for eight companies. For further details see: U.S. IPO Weekly Recap: Airbnb And DoorDash Make Their Public Debuts...
Forma Therapeutics (FMTX) has priced its public offering of 5.3M common shares at $45.25/share, for expected gross proceeds of ~$239.8M.Underwriters' over-aalotment is an additional 795K shares.Closing date is December 15. For further details see: Forma Therapeutics prices equity offeri...
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the pricing of an underwritten public offering of 5,300,000 shares of its common stock at a public offering price of $45.25 per ...
The 62nd ASH Annual Meeting and Exposition held virtually this year from December 5-8, 2020, has highlighted promising experimental therapies in biotech, enabling their developers to fortify their balance sheets through secondary offers as investors pore through the trial data.Since November ...
Forma Therapeutics (FMTX) has launched a proposed public offering of 4.6M shares. Underwriters have an option to purchase up to 690k additional shares.Price is yet to be determined. For further details see: Forma Therapeutics initiates equity offering of 4.6M shares
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it has launched a proposed public offering of 4,600,000 shares of its common stock. All of the shares of common stock i...
Forma Therapeutics ([[FMTX]] +2.9%) gains while competitor Agios Pharmaceuticals slides, after the pair presented updated data for their sickle cell disease candidates at the annual ASH meeting.FMTX’s FT-4202 data suggest a best-in-class asset as hemoglobin response rate was higher tha...
News, Short Squeeze, Breakout and More Instantly...
Forma Therapeutics Holdings Inc. Company Name:
FMTX Stock Symbol:
NASDAQ Market:
Forma Therapeutics Holdings Inc. Website:
The “Believe it!” Campaign Will be Featured on TV Networks and Radio Stations Across the U.S., Driving Viewers to SCDBelieveIT.org The Sickle Cell Disease Association of America, Inc. (SCDAA), in partnership with Forma Therapeutics, Inc. (Nasdaq: FMTX) ...
NEW YORK, NY / ACCESSWIRE / September 27, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments, Inc. (NASDAQ:EVOP...
Forma Therapeutics Holdings Inc ( NASDAQ: FMTX ) shares are up 50% after announcing a definitive agreement with Novo Nordisk. According to the agreement terms, Novo Nordisk will purchase the clinical-stage pharmaceutical firm focusing on rare blood disorders and sickle cell dise...